The identification and measurement of extractables and leachables (E&L) is a critical element of advanced therapy QC. David McCall (Senior Editor, BioInsights) speaks to Jason Creasey (Managing Director, Maven E&L Ltd) about regulators’ expectations and the importance of adopting a risk-based approach to E&L for cell therapy developers.
